Putting NICE guidance into practice

Costing statement: Sofosbuvir for chronic hepatitis C
Implementing the NICE guidance on Sofosbuvir for treating chronic hepatitis C (TA330)

Published: February 2015

NHS England commissions this technology.

The estimated cost of implementing the guidance is £106 million for the population of England. This cost includes savings from onward transmissions avoided of £10 million and resources released from reduced treatment periods £10 million. The population eligible for treatment is approximately 28,600 people per year in England.